CareMax (NASDAQ:CMAX – Get Rating) was downgraded by equities research analysts at TD Cowen from an “outperform” rating to a “market perform” rating in a research note issued to investors on Friday, Marketbeat.com reports. They currently have a $4.00 price target on the stock, down from their previous price target of $7.00. TD Cowen’s price objective suggests a potential upside of 30.51% from the company’s current price.
Several other research analysts also recently weighed in on CMAX. UBS Group decreased their target price on shares of CareMax from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, January 6th. Piper Sandler decreased their target price on shares of CareMax from $15.00 to $5.00 in a research note on Wednesday, December 14th.
CareMax Stock Down 15.8 %
CMAX opened at $3.07 on Friday. The company has a current ratio of 4.81, a quick ratio of 4.78 and a debt-to-equity ratio of 0.39. CareMax has a 52-week low of $2.77 and a 52-week high of $9.10. The company has a 50 day moving average of $4.17 and a two-hundred day moving average of $4.94.
Insider Buying and Selling
Hedge Funds Weigh In On CareMax
Several large investors have recently made changes to their positions in CMAX. HBK Sorce Advisory LLC acquired a new position in shares of CareMax in the third quarter worth about $26,000. UBS Group AG acquired a new position in shares of CareMax in the second quarter worth about $32,000. Ensign Peak Advisors Inc acquired a new position in shares of CareMax in the third quarter worth about $50,000. Legal & General Group Plc acquired a new position in shares of CareMax in the second quarter worth about $62,000. Finally, GSA Capital Partners LLP acquired a new position in shares of CareMax in the fourth quarter worth about $69,000. Institutional investors own 95.38% of the company’s stock.
CareMax, Inc provides medical services through physicians and health care professionals. It offers a suite of health care and social services to its patients, including primary care, specialty care, telemedicine, health and wellness, optometry, dental, pharmacy, and transportation. The company also provides CareOptimize, a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians in the United States.
- Get a free copy of the StockNews.com research report on CareMax (CMAX)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for CareMax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareMax and related companies with MarketBeat.com's FREE daily email newsletter.